Publication at Faculty of Physical Education and Sport, First Faculty of Medicine |
2019
Abstract
Chemotherapy is still the dominant modality of systemic treatment for urothelial carcinoma (UC) of the bladder. The single most important drug in the treatment of UC is cisplatin, usually administered in combination regimens.
However, the use of cisplatin combinations is limited by its marked nephrotoxicity. Although new treatment options have become available with the progress of immunooncology, satisfactory treatment options do not yet exist for patients progressing after chemotherapy and immunotherapy.
New targeted drugs such as enfortumab vedotin or erdafitinib have shown promiseing results in this setting.